Index

A
AAD, 165
ABCDE system, 83, 84
Activation, 122
Adjuvant radiotherapy, 106, 107
Advanced melanoma, 127
Age, 10, 33
Age-standardized rate, 5, 6, 7
Albinism, 33
Anatomic distribution, 12
Antigen presenting cell, 122
Attenuative type, 67

B
BAD, 166
Basic science, 121
Biology, 123
Biomarkers, 39, 130
Biopsy, 84, 93
Body sites, 28
BRCA2 mutation, 81

C
CDKN2A, 81
Chemotherapy, 147
Chest X-ray, 169
Clark’s levels, 85
Cleft formation, 68
Clinical application, 121
Clinical presentation, 79
Clinical, 82
Clinically negative, 93
Concomitant agents, 109
Computed tomography, 171
Congenital melanocytic nevi, 81
Consumption of epidermis, 68
CTLA-4, 123, 124
Cyclooxygenase-2, 45

D
Detection, 145
Diagnosis, 34, 82
Diagnostic strategies, 84
Disease types, 85

E
Elective lymph node dissection, 95
ELND, 95
Embryonic phenotype, 60
Endogenous enzyme inhibitors, 47
Enzyme markers, 47
Enzymes, 42
Epidemiology, 3, 23
Epidermal hyperplasia, 69
Epidermal involvement, 70
Epidermis, 68
ESMO, 165
Ethnicity, 5
Etiology, 80

F
FAMMM, 81
Fitzpatrick classification, 83
Index

G
Genetics, 33
Geography, 5, 24
GMMANZ, 167
Guidelines for excision, 92
Guidelines, 165

H
Heterogeneity, 57
Heterogeneous, 59, 71
Histologic confirmation, 84
Historical perspective, 102
HIV, 32

I
Imaging, 169
Immune checkpoint inhibitors, 121
In transit metastatic disease, 97
Incidence, 5, 26
Increased risk, 81
Indications, 94
Infiltrative type, 67
Ipilimumab, 127

L
Laboratory tests, 168
Lactate dehydrogenase, 43
Lentigo maligna, 104
Liposomes, 148
Localized disease, 92
Long-term management, 161
Lymph node ultrasonography, 170
Lymphadenectomy, 95, 96

M
Magnetic resonance imaging, 171
Malignant melanoma, 39
Management, 161
Margins for surgical excision, 93
Matrix metalloproteinases, 46
Melanocytes, 4, 80
Melanoma, 3, 23, 39, 57, 67, 79, 91, 101, 121, 143
Metabolites, 43
Metastatic melanoma, 97
MOHS micrographic surgery, 92
Mortality, 13, 34
Mucosal melanomas, 104

N
Nevi, 31
Nano therapies, 147
Nanohydrogels, 148
Nanomedicine, 143
NCCN, 165
Ninosomes, 148
Nivolumab, 131
Nodalm 61, 107
Nonprotein biomarkers, 50
Nucleic acids, 43

O
Ocular melanomas, 105

P
Palliative radiotherapy, 107
Patient history, 82
PD-1, 126, 128, 131
Pembrolizumab, 131
Physical examination, 83
Plasticity, 57
Polymeric nanoparticles, 147
Population, 26, 81
Positron emission tomography, 171
Predictions, 12
Prevention, 14
Primary prevention, 15
Progenitor markers, 43, 49
Prognostic factors, 85
Prognostic impact, 67, 72
Proliferation, 68

R
Radiation therapy, 101
Radiotherapy, 147
Reactive hyperplasia, 67, 69
Recommendations, 82
Re-epithelialization, 67, 69
Regional lymph nodes, 93
Resistance, 133
Resolved ulceration, 69
Risk factors, 29, 80

S
S100 proteins, 43, 48
SBRT, 101, 103
Screening, 80, 82
Secondary prevention, 15
Secreted proteins, 42
Sentinel lymph node biopsy, 93
Sentinel node, 94
Sex, 10, 32
Short-term management, 161
SLNB, 93, 94
South Africa, 23, 24
SRS, 101, 103
Stage, 34
Staging, 86, 87
Stem cell markers, 43, 49
Stem cell, 62
Stereotactic body radiotherapy, 101, 103
Stereotactic radiosurgery, 101, 103
Subtypes, 85
Sun exposure, 31
Surgical consideration, 96
Surgical management, 91
Surveillance, 162
Swiss guidelines, 167

T
TCE, 162
T-cell responses, 122
TCP, 167
Theranostic nanomedicine, 148
Total cutaneous examination, 162
Total cutaneous photography, 167
Toxicity, 125, 129
Trauma, 31
Treatment, 121, 145
Trends, 12
Tyrosinase, 44

U
Ulcerated melanoma, 67
Ulceration, 68
Ultraviolet, 5

V
Vascular phenotype, 58

W
Weather, 25

X
Xeroderma pigmentosum, 81
Dr. William H. Ward is a fellow in complex general surgical oncology at Fox Chase Cancer Center in Philadelphia. An active-duty naval officer, Dr. Ward completed internship in 2008 and aeromedical training in 2009. Designated a Naval Flight Surgeon, he was assigned to Marine Tactical Electronic Warfare Squadron 3 until 2011. He completed general surgery residency at Naval Medical Center Portsmouth in 2015 and served as Ship’s Surgeon, USS George H.W. Bush, until 2016. Dr. Ward is Assistant Professor of Surgery, F. Edward Hebert School of Medicine, Uniformed Services University and an associate fellow of the American College of Surgeons.

Dr. Jeffrey M. Farma completed general surgery residency at Temple University, surgical oncology research fellowship at National Cancer Institute, Bethesda, Maryland, and clinical surgical oncology fellowship at Moffitt Cancer Center, Tampa, Florida. He joined the Department of Surgical Oncology, Fox Chase Cancer Center in 2009 and is an Associate Professor of Surgical Oncology. Dr. Farma serves as Program Director, Complex General Surgical Oncology Fellowship and Surgical Director, Melanoma and Skin Cancer Program. He was awarded the 2016 Melanoma Research Foundation Humanitarian Award, is a fellow of the American College of Surgeons, Association of Academic Surgeons and Society of University Surgeons.